Alexandra Robertson

1 week ago | law.com | Edward E. Neiger |Alexandra Robertson |David Stern

The authors write "Suboxone is the brand name of combination of Buprenorphine and Naloxone, manufactured by Indivior, Inc., and used in the treatment of opioid dependence. In January of 2022, the FDA issued a drug safety communication about long term Suboxone sublingual film use and the increased risk of serious dental problems. FDA ordered that a new warning about the risk of dental problems be added to the Suboxone prescribing information and patient medication guide.